课题基金 / 基金详情

prline-rich endogenous antimicrobial peptide suppresses colon carcinoma cell proliferation by adaptor molecule competition

prline-rich endogenous antimicrobial peptide suppresses colon carcinoma cell proliferation by adaptor molecule competition
富含脯氨酸的内源性抗菌肽通过接头分子竞争抑制结肠癌细胞增殖
批准号:
12670452
负责人:
FUJIMOTO Yoshinori
金额:
$2.24万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001

项目摘要

项目成果

FUJIMOTO Yoshinori的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PR-39, which is an endogenous antimicrobial peptide, can bind to Src homology 3 domains of the NADPH complex protein p47phox and the signaling adapter protein p130Cas. Recently, we have reported that PR-39, gene transduction altered invasive activity and actin structure on human hepatocellular carcinoma cells, suggesting that this peptide affects cellular signaling pathway due to its proline-rich motif. In order to clarify the mechanism of the PR-39 functions, we transfected with PR-39 gene into mouse NIH3T3 cells which were already transformed with human activated k-ras gene. The PR-39 gene transfectant showed a reorganization of actin structure and suppression of cell proliferation both in vitro and in vivo. Co-immunoprecipitation analysis revealed that the PR-39 binds to PI3-kinase p85a, which is a regulatory subunit of PI3-kinase and one of the effectors by which ras induces cytoskeletal changes and stimulates the mitogenesis. PI3-kinase activity of the PR-39 gene transfectant was decreased compared with that of the ras transformant. These results suggest that the PR-39 alters actin structure and cell proliferation rate by binding to PI3-kinase p85a and suppressing the PI3-kinase activity, The PR-39 gene transfectant derived from colon carcinoma cells also showed the morphological change and the suppression of the proliferation in vitro and vivo, suggesting that PR-39 might be a candidate for the targeting therapy of cancers.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Tanaka K.: "PI3-kinaze p85a is a target molecule of proline-rich antimierobial pepLide to sunpress cell proliferation on ras-transformed cells"Jpn J Cancer Res. 92. 959-967 (2001)
Tanaka K.:“PI3-kinaze p85a 是富含脯氨酸的抗微生物肽的靶分子,可抑制 ras 转化细胞上的细胞增殖”Jpn J Cancer Res。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
藤本 佳範: "内因性抗菌ペプチドPR-39遺伝子のras transformantに及ぼす細胞増殖抑制機能について"Biotherapy. 14. 511-513 (2000)
藤本义德:“内源性抗菌肽PR-39基因对ras转化体的细胞增殖抑制功能”生物疗法14. 511-513(2000)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Tanaka K.: "PI3-kinase p85a is a target molecule of proline-rich antimicrohial peptide to suppress cell proliferation on ras-transformed cells"Jpn J Cancer Res. 92. 959-967 (2001)
Tanaka K.:“PI3-激酶 p85a 是富含脯氨酸的抗微生物肽的靶分子,可抑制 ras 转化细胞的细胞增殖”Jpn J Cancer Res。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Molecular analysis of the neuropathic pain state using sns-null mutant mice
  • 批准号:
    13470313
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 资助金额:
    $7.55万
  • 财政年份:
    2001
  • 负责人:
    FUJIMOTO Yoshinori
  • 依托单位:
Studies on the evaluation and development of Colombian Medicinal Plants
  • 批准号:
    12576030
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 资助金额:
    $9.6万
  • 财政年份:
    2000
  • 负责人:
    FUJIMOTO Yoshinori
  • 依托单位:
3-dimensional Analysis for Conduction Blocks of the Spinal Cord with Multi-channel Superconducting Quantum Interference Device.
  • 批准号:
    11557109
  • 项目类别:
    Grant-in-Aid for Scientific Research (B).
  • 资助金额:
    $8.58万
  • 财政年份:
    1999
  • 负责人:
    FUJIMOTO Yoshinori
  • 依托单位:
PR-39 gene transduction suppresses heaptocellular carcinoma cell metastasis by inhibition of signal transduction
  • 批准号:
    10670444
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $1.86万
  • 财政年份:
    1998
  • 负责人:
    FUJIMOTO Yoshinori
  • 依托单位:
国内基金
海外基金
猪源PR-39调控五指山猪肠道乳杆菌有机酸代谢保护肠黏膜屏障功能的分子机制
  • 批准号:
    --
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    32万元
  • 批准年份:
    2022
  • 负责人:
    张海文
  • 依托单位:
乳铁蛋白对仔猪骨髓抗菌肽PR-39基因表达的影响
  • 批准号:
    30571348
  • 项目类别:
    面上项目
  • 资助金额:
    27.0万元
  • 批准年份:
    2005
  • 负责人:
    汪以真
  • 依托单位: